# Pizarra — PT-pseudo_25007bb807d7 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_25007bb807d7
Task: 1

Encounter: Urology - outpatient on 19 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 17.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.462 ng/mL²
  - PSA velocity: 1.29 ng/mL/yr
  - Prior PSA: 16.1 ng/mL
  - Prostate volume: 36.82 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.85766834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.

Vitals: weight 83 kg, height 193 cm, BMI 22.3, BP 122/68 mmHg, HR 74 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2015).

Chief complaint: Persistent prostate-specific antigen elevation prompted mpMRI scheduling.

History: A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications.

Physical examination: DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly.

Patient info: office administrator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 11 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.88 +/- 0.11   (95% CI 0.60-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.04  (few labelled cases resemble this one)
  - 8.0 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=17.0, age=61.0, psad=0.462, dre_ord=0.0, vol=36.82, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS=5, PSA=17.0, csPCa probability=0.85766834, DRE=Normal) and failed to incorporate the PSA velocity (1.29 ng/mL/yr), the PSA density (0.462 ng/mL²), and the context of the guideline criteria regarding biopsy-naïve status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability, but the guideline criterion is based on PI-RADS $\ge 3$, which is met, yet the prior ignores the context of the patient being biopsy-naive and the potential for overdiagnosis suggested by the guideline discussion on PI-RADS 3-5 lesions. The prior's high probability might be inflated because it does not account for the uncertainty associated with the PI-RADS 5 score in the context of a biopsy-naive patient.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology consultation notes

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_25007bb807d7", "radiology_report": "Subject: mpMRI Prostate\nDate: 15 January 2025\nFacility: Amsterdam UMC (VUmc location)\n\nClinical indication: Evaluation of elevated PSA (17.0 ng/mL) and clinical suspicion of malignancy.\n\nFINDINGS: The gland measures 36.82 mL in total volume. T2-weighted sequences highlight a distinct, 18 mm hypointense focus within the right peripheral zone, spanning the base to mid-gland. Diffusion-weighted imaging reveals pronounced restriction with corresponding ADC hypointensity. Dynamic contrast-enhanced phases demonstrate early, focal arterial enhancement localized to the lesion. There is no evidence of extraprostatic extension, seminal vesicle invasion, or pelvic lymphadenopathy.\n\nIMPRESSION: PI-RADS 5 lesion in the right peripheral zone. Prostate volume 36.82 mL yielding a PSA density of 0.462 ng/mL/mL. csPCa predicted probability 0.85766834"}
get_psa_trend
{"case_id": "PT-pseudo_25007bb807d7", "psa_trend": [{"date": "Jun 2022", "val": 5.7}, {"date": "Jan 2023", "val": 11.3}, {"date": "Sep 2023", "val": 15.4}, {"date": "May 2024", "val": 3.1}, {"date": "Jan 2025", "val": 17.0}]}
get_previous_notes
{"case_id": "PT-pseudo_25007bb807d7", "previous_notes": [{"date": "21 Sep 2024", "author": "Dr. R. van den Berg (GP)", "text": "The patient was reviewed following a PSA reading of 16.1 ng/mL in May 2024. Symptoms remain minimal with an IPSS score of four, and cross-sectional imaging was arranged to clarify the aetiology of the persistent elevation. A routine urinalysis was unremarkable ahead of the planned urology visit."}, {"date": "25 Jan 2024", "author": "Dr. R. van den Berg (GP)", "text": "Follow-up consultation regarding a PSA of 15.3 ng/mL obtained in September 2023. The gentleman reports only mild voiding frequency without nocturia or urgency, and a repeat PSA was arranged to monitor the trajectory."}]}
get_lab_results
{"case_id": "PT-pseudo_25007bb807d7", "laboratory_results": [{"name": "PSA", "val": "17.0 ng/mL", "date": "05 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.60 ng/mL", "date": "05 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "05 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "15.7 g/dL", "date": "05 Dec 2024", "flag": ""}, {"name": "WBC", "val": "7.9 x10^9/L", "date": "05 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "224 x10^9/L", "date": "05 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "91 umol/L", "date": "05 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "05 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "15.4 nmol/L", "date": "05 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "66 U/L", "date": "05 Dec 2024", "flag": ""}, {"name": "LDH", "val": "128 U/L", "date": "05 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for the biopsy decision per the retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the right peripheral zone, 18 mm size, with diffusion restriction and arterial enhancement.
- PSA trend: Rising trajectory from 3.1 ng/mL in May 2024 to 17.0 ng/mL in Jan 2025 (velocity of 1.29 ng/mL/yr).
- Guideline criterion: PI-RADS 5 lesion mandates biopsy according to the criterion (PI-RADS $\ge 3$).

AGAINST sampling this patient now:
- Previous notes: Patient is biopsy-naive, and no prior biopsy grade is documented.

WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the high-risk PI-RADS 5 finding and the rising PSA velocity, aligning with the expert protocol criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is strongly supported by the PI-RADS 5 finding, which meets the guideline criterion for sampling. This is further reinforced by the rising PSA trajectory, showing a velocity of 1.29 ng/mL/yr, and the PSA level of 17.0 ng/mL. The statistical prior also suggested biopsy, and the retrieved mpMRI report confirmed a high-risk lesion, leading to convergence on the biopsy recommendation.

Variables that carried weight: age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
